Fig 1: BRCA1 interacts with the linker histone H1 upon treatment with hydroxyurea (HU).(A) Western blot analysis of GFP immunoprecipitations (IPs) from HEK293 cells transfected with GFP-BRCA1 and FLAG-H1.3 and treated or not with 10 Gy ionizing radiation. After SDS–PAGE and PVDF transfer, membranes were incubated with antibodies against the indicated proteins. (B) Western blot analysis of GFP IPs from HEK293 cells transiently transfected with GFP-BRCA1 and FLAG-H1.3 and treated or not with 3 mM HU for 2 h. After SDS–PAGE and PVDF transfer, membranes were incubated with antibodies against the indicated proteins. (C) Western blot analysis of GFP IPs from HEK293 cells transiently transfected with GFP-BRCA1 WT (left panel) or S1336A mutant (right panel), and FLAG-H1.3 and treated or not with 3 mM HU for 2 h. After SDS–PAGE, Western blotting was performed using antibodies against the indicated proteins. (D) Western blot analysis of GFP IPs from HEK293 cells transiently transfected with GFP-BRCA1 and FLAG-H1.1 and treated or not with 3 mM HU for 2 h. After SDS–PAGE, Western blotting was performed using antibodies against the indicated proteins. (E) IP of endogenous H1.3 from human U2OS cells treated or not with 3 mM HU for 2 h. After SDS–PAGE, Western blotting was performed using antibodies against the indicated proteins. (F) Left: representative pictures of proximity ligation assays (PLA) performed with antibodies against endogenous BRCA1 and H1.2 in U2OS cells treated or not with HU; scale bar = 10 μM. Right: quantification of PLA staining showing a number of PLA foci per nucleus in U2OS cells treated or not with HU.
Fig 2: H1.2 knock-down causes a reduction in nucleosome spacing.(A) Nuclei from H1 variant knock-down cells treated or not with Dox for 6 days were treated with MNase and the profile of bulk chromatin was analyzed in gel electrophoresis to calculate the nucleosome repeat length (NRL). (B) Plot of nucleosome number versus DNA length for MNase-digested bulk chromatin of H1.2 knocked-down cells ±Dox. This plot has been used to calculate the corresponding NRL. Data from 5 independent experiments has been pooled. Average±SD is shown. Data from untreated and treated samples differed significantly in a t-Student test (95% confidence interval with a p value of 0.0001). Open triangles denote untreated, and solid square symbols correspond to cells treated for 6 days with Dox. (C) Complementation of reduced nucleosome spacing in H1.2 knocked-down cells by stable expression of shRNA-resistant H1.2 (rH1.2HA).
Fig 3: H1.2 PARylation permits its displacement from chromatin upon DNA damage. a HeLa cells were transfected with GFP-H1.2 and treated with 20 μM Ku55933 or 2 μM Ku57788 for 4 h or 5 μM PJ34 for 1 h followed by laser micro-irradiation. Images were taken every 10 s for 5 min and quantifications of the IR path signal intensity were shown and ~15 IR paths from 10 separate cells were calculated. The data represent the mean ± SD. Scale bars, 10 μm. b HeLa cells were transfected with the indicated siRNAs and treated with 40 μM etoposide for the indicated time. Chromatin was fractionated and analyzed by immunoblotting. c Parp1 wild-type (+/+) or KO (−/−) MEFs were treated with 40 μM etoposide for the indicated time and chromatin was fractionated and analyzed by immunoblotting. d HeLa cells were transfected with FLAG-H1.2 and treated with 40 μM etoposide for 15 min with or without 5 μM PJ34 for 1 h. Cell extracts were immunoprecipitated with FLAG-conjugated M2 beads. e Recombinant HIS-H1.2 was subjected to in vitro PARylation assay in the presence of NAD+ or 10 μM PJ34, as indicated. f HeLa cells were transfected with wild-type or S188A mutated FLAG-H1.2 and treated with 40 μM etoposide for 15 min with or without 5 μM PJ34 for 1 h, as indicated. Cells were extracted and immunoprecipitated with FLAG-conjugated M2 beads. g Recombinant wild-type, S188A mutated or C1-deleted (ΔC1) HIS-H1.2 were subjected to in vitro PARylation assay. h HeLa cells were transfected with wild-type, ΔC1 or S188A mutated GFP-H1.2 and subjected to laser micro-irradiation. Images were taken every 20 s for 5 min and representative images were shown. Quantifications were calculated as in a. The data represent the mean ± SD. Scale bars, 10 μm
Fig 4: Select chromatin proteins in hyperosmotic sucrose incubated HL-60/S4 Cells. Confocal immunostaining in the absence/presence of 300 mM sucrose, stained with rabbit antibodies against H1.2, H1.5, HMGN2 and HMGB2 (all green), and counterstained with PL2-6 (red) and DAPI (blue). (a-d) stained with anti-H1.2; (e,f), anti-H1.5; (g-j), anti-HMGN2; (k,l), anti-HMGB2, (a,c,e,g,i,k), 0 mM sucrose; (b,d,f,h,j,l), 300 mM sucrose. Magnification bars, 10 µm.
Fig 5: BRCA1 interacts with histone H1 upon treatment with HU.(A) Western blot analysis of GFP immunoprecipitations (IPs) from HEK293 cells transfected with GFP-BRCA1 (1–1,071) or GFP-BRCA1 (1,063–1,863), and FLAG-H1.3 and treated or not with 3 mM HU for 2 or 4 h. After SDS–PAGE and PVDF transfer, membranes were incubated with antibodies against the indicated proteins. (B) Western blot analysis of GFP IPs from HEK293 cells transiently transfected with GFP-BRCA1 and FLAG-H1.4 and treated or not with 3 mM HU (hydroxyurea) for 2 h. After SDS–PAGE and PVDF transfer, membranes were incubated with antibodies against the indicated proteins. (C) IP of endogenous H1.2 from human U2OS cells treated or not with 3 mM HU for 2 h. After SDS–PAGE, Western blotting was performed using antibodies against the indicated proteins. (D) Left: representative pictures of proximity ligation assays (PLA) performed with antibodies against endogenous BRCA1 and H1.3 in U2OS cells treated or not with HU. Right: quantification of PLA staining showing a number of PLA foci per nucleus in U2OS cells treated or not with HU; unpaired t test analysis: ****P < 0.0001; scale bar = 10 μM. (E) IP of endogenous H1.3 from human U2OS cells transfected with CTR siRNA or siRNA against RNF8 and treated or not with 3 mM HU for 2 h. After SDS–PAGE, Western blotting was performed using antibodies against the indicated proteins.
Supplier Page from Abcam for Anti-Histone H1.2 antibody